VTGN

Vistagen Therapeutics, Inc. VTGN

NasdaqSmall CapHealthcare

13F Pro quality score

Rank #2,877 of 2,925

Why it scores 10Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$1.48M

Quarter to Jun 30

Net income

$-13.03M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$2.54M total
Commodore Capital LP
$630.2KNew
VANGUARD CAPITAL MANAGEMENT LLC
$355.8K0.0%
TWO SIGMA INVESTMENTS, LP
$191.6K+80.6%
ACADIAN ASSET MANAGEMENT LLC
$178.0K+34.8%
RENAISSANCE TECHNOLOGIES LLC
$165.1K+150.8%
Ikarian Capital, LLC
$117.3K0.0%
AdvisorShares Investments LLC
$99.1K+58.3%
LUMINUS MANAGEMENT LLC
$91.1K+1.8%
GEODE CAPITAL MANAGEMENT, LLC
$82.5K-19.5%
ADAR1 Capital Management, LLC
$79.4K-53.3%
BlackRock, Inc.
$78.1K-23.0%
GROUP ONE TRADING, L.P.
$68.8K+1431.5%
Verdad Advisers, LP
$66.3K+58.6%
VANGUARD FIDUCIARY TRUST CO
$49.2K0.0%
JANE STREET GROUP, LLC
$37.3K-39.6%
BOOTHBAY FUND MANAGEMENT, LLC
$30.4K0.0%
STATE STREET CORP
$27.4K0.0%
XTX Topco Ltd
$26.8K-22.6%
NORTHERN TRUST CORP
$18.3K+11.2%
StemPoint Capital LP
$17.3K0.0%
CITADEL ADVISORS LLC
$15.6KNew
Virtu Financial LLC
$15.0KNew
UBS Group AG
$13.1K-26.6%
GSA CAPITAL PARTNERS LLP
$12.0K+9.5%
OSAIC HOLDINGS, INC.
$10.1K+961.9%
See all 49 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q1 2027
EDGAR

Net Income

Q1 2027
EDGAR

EPS (Diluted)

Q1 2027
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/VTGN

Earnings Per Share

13fpro.ai/company/VTGN

Loading ratio trend…

VTGN key financials by period

Reported revenue, net income and operating margin by fiscal year, from Vistagen Therapeutics, Inc.'s annual filings on SEC EDGAR.

Vistagen Therapeutics, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2026$1.3M$-69.7M—
FY 2025$486.0K$-51.4M—
FY 2024$1.1M$-29.4M—
FY 2023$-227.0K$-59.2M—
FY 2022$1.1M$-47.8M—
FY 2021$1.1M$-17.9M—
Source: VTGN filings on SEC EDGAR →

VTGN insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Vistagen Therapeutics, Inc. (VTGN): stock profile, AI score and financials

Vistagen Therapeutics, Inc. (VTGN) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores VTGN at 9.8/100 on a composite quality score built from its SEC filings, placing it at rank #2,877 of 2,925 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q1 2027), Vistagen Therapeutics, Inc. reports quarterly revenue of $1.5M, net income of $-13.0M. Top institutional holders of VTGN by reported 13-F value include Commodore Capital, VANGUARD CAPITAL MANAGEMENT, TWO SIGMA INVESTMENTS, based on the most recent SEC filings. VTGN trades on the Nasdaq exchange and files with the SEC under CIK 1411685. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VTGN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Vistagen Therapeutics, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1411685 →